Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbix Biosystms ( (TSE:MBX) ) has issued an update.
Microbix Biosystems Inc., a Mississauga-based life sciences manufacturer, supplies antigens, quality assessment products, and reference materials to the global diagnostics industry, supporting clinical labs, diagnostic developers, and accreditation bodies in more than 30 countries. The company, which generated C$18.6 million in fiscal 2025, also develops proprietary therapies and diagnostic reagents, including the thrombolytic drug candidate Kinlytic and DxTM sample collection products, under multiple international quality and regulatory certifications.
Microbix reported that 27.44% of its outstanding shares were represented at its March 25 annual meeting, where shareholders approved all resolutions, including the re-election of the existing board slate and the reappointment of Ernst & Young LLP as auditors with 96.66% support. The strong backing for management and directors, despite a notable minority withholding votes from one director, underscores continuity in governance and oversight as the company pursues its diagnostics and biologics growth strategy, with meeting materials and presentations made available on its website and regulatory filing platform.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.
The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.
To see Spark’s full report on MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences company that develops proprietary biological products for human health, generating C$18.6 million in revenue in fiscal 2025 and employing over 120 staff. It supplies critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and its Quality Assessment Products (QAPs) and QUANTDx reference materials, which support clinical lab proficiency testing, assay development, and diagnostic workflow quality across more than 30 countries.
The company’s antigens power antibody tests for roughly 100 diagnostic manufacturers, while its QAPs and QUANTDx lines are sold to accreditation bodies, diagnostics firms, and clinical laboratories. Microbix is ISO 9001 and 13485 certified, registered with key regulators in the U.S., Australia, and Canada, offers IVDR-compliant CE-marked products, and also advances proprietary assets such as the Kinlytic urokinase thrombolytic drug and DxTM molecular diagnostic collection reagents from its headquarters in Mississauga, Ontario, where its shares trade on the TSX and OTCQX markets.
Average Trading Volume: 56,454
Technical Sentiment Signal: Sell
Current Market Cap: C$33.25M
For detailed information about MBX stock, go to TipRanks’ Stock Analysis page.